Technical Analysis for CLRB - Cellectar Biosciences, Inc.

Grade Last Price % Change Price Change
F 2.03 -0.49% -0.01
CLRB closed down 0.49 percent on Friday, November 1, 2024, on 62 percent of normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Earnings Movers Other 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Gapped Down Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Bollinger Band Squeeze Range Contraction -0.49%
Doji - Bullish? Reversal -0.49%
Earnings Movers Other -0.49%
BB Squeeze + Lower Band Touch Range Contraction -0.49%
Lower Bollinger Band Touch Weakness -0.49%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 20 hours ago
60 Minute Opening Range Breakdown about 23 hours ago
10 DMA Resistance about 24 hours ago
Rose Above 10 DMA about 24 hours ago
Up 1% about 24 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cellectar Biosciences, Inc. Description

Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Imaging Oncology Stem Cell Chemotherapy Radiation Occupational Safety And Health Antineoplastic Drugs Blastoma Radiation Therapy Glioblastoma Targeted Therapy Advanced Solid Tumors Tomography Imaging Agent Positron Emission Tomography Cancer Stem Cell Cancer Stem Cells

Is CLRB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.45
52 Week Low 1.82
Average Volume 224,741
200-Day Moving Average 2.87
50-Day Moving Average 2.09
20-Day Moving Average 2.08
10-Day Moving Average 2.06
Average True Range 0.09
RSI (14) 44.75
ADX 8.06
+DI 15.22
-DI 18.72
Chandelier Exit (Long, 3 ATRs) 1.98
Chandelier Exit (Short, 3 ATRs) 2.24
Upper Bollinger Bands 2.15
Lower Bollinger Band 2.00
Percent B (%b) 0.18
BandWidth 6.83
MACD Line -0.02
MACD Signal Line -0.01
MACD Histogram -0.0044
Fundamentals Value
Market Cap 24.95 Million
Num Shares 12.3 Million
EPS -3.26
Price-to-Earnings (P/E) Ratio -0.62
Price-to-Sales 0.00
Price-to-Book 2.67
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.17
Resistance 3 (R3) 2.16 2.12 2.14
Resistance 2 (R2) 2.12 2.08 2.12 2.13
Resistance 1 (R1) 2.07 2.06 2.10 2.08 2.13
Pivot Point 2.03 2.03 2.04 2.03 2.03
Support 1 (S1) 1.98 1.99 2.01 1.99 1.93
Support 2 (S2) 1.94 1.97 1.94 1.93
Support 3 (S3) 1.89 1.94 1.92
Support 4 (S4) 1.90